Share on StockTwits

Research analysts at William Blair upped their target price on shares of InterMune (NASDAQ:ITMN) from $48.00 to $55.00 in a report released on Friday. William Blair’s price objective would suggest a potential upside of 27.67% from the stock’s previous close.

In other InterMune news, CEO Daniel G. Welch sold 171,025 shares of the company’s stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $44.98, for a total transaction of $7,692,704.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of other analysts have also recently weighed in on ITMN. Analysts at Stifel Nicolaus raised their price target on shares of InterMune from $51.00 to $53.00 in a research note on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Robert W. Baird raised their price target on shares of InterMune from $44.00 to $50.00 in a research note on Thursday. Finally, analysts at Jefferies Group raised their price target on shares of InterMune from $22.00 to $25.00 in a research note on Thursday. They now have an “underperform” rating on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $44.85.

Shares of InterMune (NASDAQ:ITMN) traded down 0.81% during mid-day trading on Friday, hitting $43.08. 1,932,931 shares of the company’s stock traded hands. InterMune has a 1-year low of $10.95 and a 1-year high of $47.72. The stock has a 50-day moving average of $43.87 and a 200-day moving average of $33.60. The company’s market cap is $4.274 billion.

InterMune (NASDAQ:ITMN) last announced its earnings results on Wednesday, August 6th. The company reported ($0.72) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter last year, the company posted ($0.77) earnings per share. InterMune’s revenue was up 141.2% compared to the same quarter last year. Analysts expect that InterMune will post $-2.54 EPS for the current fiscal year.

InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.